RDHL (Redhill Biopharma Ltd.) Stock Analysis - Financials

Redhill Biopharma Ltd. (RDHL) is a publicly traded Healthcare sector company. As of May 21, 2026, RDHL trades at $0.91 with a market cap of $4.85M and a P/E ratio of 0.00. RDHL moved -0.98% today. Year to date, RDHL is -34.36%; over the trailing twelve months it is -51.63%. Its 52-week range spans $0.71 to $9.25. Rallies surfaces RDHL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are RDHL's key financials?

RDHL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RDHL recently traded at $0.91. Market cap is $4.85M. P/E ratio is 0.00. Revenue is $0.

RDHL Key Metrics

Key financial metrics for RDHL
MetricValue
Price$0.91
Market Cap$4.85M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$9.25
52-Week Low$0.71
Volume2.19K
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Latest RDHL News

Recent RDHL Insider Trades

  • Raday Gilead sold 15.74M (~$1.57K) on Apr 6, 2026.

RDHL Analyst Consensus

RDHL analyst coverage data. Average price target: $0.00.

Common questions about RDHL

What are RDHL's key financials?
RDHL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RDHL recently traded at $0.91. Market cap is $4.85M. P/E ratio is 0.00. Revenue is $0.
Is RDHL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RDHL. It does not provide personalized investment advice.
RDHL

RDHL